Document Detail


Effects of amylin and bupropion/naltrexone on food intake and body weight are interactive in rodent models.
MedLine Citation:
PMID:  23178527     Owner:  NLM     Status:  Publisher    
Abstract/OtherAbstract:
Antagonism of opioid systems (e.g., with naltrexone) has been explored as an anti-obesity strategy, and is particularly effective when co-administered with dual inhibitors of dopamine and norepinephrine reuptake (e.g., bupropion). Previously, we demonstrated that amylin enhances the food intake lowering and weight loss effects of neurohormonal (e.g., leptin, cholecystokinin, melanocortins) and small molecule (e.g., phentermine, sibutramine) agents. Here, we sought to characterize the interaction of amylin with naltrexone/bupropion on energy balance. Wild-type and amylin knockout mice were similarly responsive to the food intake lowering effects of either naltrexone (1mg/kg, subcutaneous) or bupropion (50mg/kg, subcutaneous) suggesting that they act independently of amylinergic systems and could interact additively when given in combination with amylin. To test this, diet-induced obese rats were treated (for 11 days) with vehicle, rat amylin (50μg/kg/d, infused subcutaneously), naltrexone/bupropion (1 and 20mg/kg, respectively by twice daily subcutaneous injection) or their combination. We found that amylin+naltrexone/bupropion combination therapy exerted additive effects to reduce cumulative food intake, body weight and fat mass. In a separate study, the effects of amylin and naltrexone/bupropion administered at the same doses (for 14 days) were compared to a pair-fed group. Although the combination and pair-fed groups lost a similar amount of body weight, rats treated with the combination lost 68% more fat and better maintained their lean mass. These findings support the strategy of combined amylin agonism with opioid and catecholaminergic signaling systems for the treatment of obesity.
Authors:
Jason R Clapper; Jennifer Athanacio; Carrie Wittmer; Pete S Griffin; Lawrence D'Souza; David G Parkes; Jonathan D Roth
Related Documents :
2760367 - Food group contributions to nutrient intake in whites, blacks, and mexican americans in...
19707227 - Cultural, socioeconomic and nutritional determinants of functional food consumption pat...
23839907 - Methylphenidate decreases fat and carbohydrate intake in obese teenagers.
20126297 - Whole grain intake: the baltimore longitudinal study of aging.
19732987 - Contamination with storage fungi of human food from cameroon.
965337 - Colorimetric reagents for determining vitamin a in feeds and foods.
Publication Detail:
Type:  JOURNAL ARTICLE     Date:  2012-11-21
Journal Detail:
Title:  European journal of pharmacology     Volume:  -     ISSN:  1879-0712     ISO Abbreviation:  Eur. J. Pharmacol.     Publication Date:  2012 Nov 
Date Detail:
Created Date:  2012-11-26     Completed Date:  -     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  1254354     Medline TA:  Eur J Pharmacol     Country:  -    
Other Details:
Languages:  ENG     Pagination:  -     Citation Subset:  -    
Copyright Information:
Copyright © 2012. Published by Elsevier B.V.
Affiliation:
Amylin Pharmaceuticals, LLC., San Diego, CA, USA.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Maintenance of amphetamine-induced place preference does not correlate with astrocytosis.
Next Document:  Genistein: A promising therapeutic agent for obesity and diabetes treatment.